Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Change in Acquisitions & Divestments: 2021-2024

Historic Change in Acquisitions & Divestments for Foghorn Therapeutics (FHTX) over the last 4 years, with Dec 2024 value amounting to $232.5 million.

  • Foghorn Therapeutics' Change in Acquisitions & Divestments fell 37.63% to $39.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $258.5 million, marking a year-over-year increase of 20.64%. This contributed to the annual value of $232.5 million for FY2024, which is 5.87% up from last year.
  • Latest data reveals that Foghorn Therapeutics reported Change in Acquisitions & Divestments of $232.5 million as of FY2024, which was up 5.87% from $219.6 million recorded in FY2023.
  • Foghorn Therapeutics' 5-year Change in Acquisitions & Divestments high stood at $232.5 million for FY2024, and its period low was $139.5 million during FY2021.
  • In the last 3 years, Foghorn Therapeutics' Change in Acquisitions & Divestments had a median value of $219.6 million in 2023 and averaged $206.1 million.
  • Data for Foghorn Therapeutics' Change in Acquisitions & Divestments shows a peak YoY spiked of 32.09% (in 2023) over the last 5 years.
  • Foghorn Therapeutics' Change in Acquisitions & Divestments (Yearly) stood at $139.5 million in 2021, then climbed by 19.19% to $166.2 million in 2022, then soared by 32.09% to $219.6 million in 2023, then rose by 5.87% to $232.5 million in 2024.